BCL2L12 and cancer: Investigations on LN229, LNZ308, and U87MG cell lines derived from xenografted tumors referred that miR-182-SNAs downregulated the expression of the Bcl2L12 gene in GBM through binding to the 3′ UTR of Bcl2L12, exerting inhibitory effects on caspase-3, and caspase-7, and finally, resulting in (1) a reduction in tumor burden, by reducing the number of proliferating (Ki67) and enhancing the number of apoptotic (caspase-3) cancer cells, and (2) improving animal survival in vivo without noteworthy undesirable side effects [160].